-
April 4, 2018PREVIEW
FDA has approved exenatide extended-release (ER) for injectable suspension as add-on...
April 2, 2018PREVIEWOn March 29, 2018, FDA approved the use of sargramostim under the...
March 29, 2018PREVIEWFDA granted accelerated approval to blinatumomab to treat adults and children with B-cell precursor acute...
March 29, 2018PREVIEWMylan announced FDA approval of efavirenz, lamivudine, and tenofovir...
March 27, 2018PREVIEWNovartis announced FDA approval of nilotinib to include treatment...
Pages
2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351
© 2013 American Pharmacists Association All Rights Reserved.
About the American
Pharmacists Association
The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.
About APhA DrugInfoLine
APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.
